The induction of urothelial hyperplasia by methyl methanesulphonate and ethyl methanesulphonate. by Tudor, R. J. et al.
Br. J. Cancer (1983), 48, 289-300
The induction of urothelial hyperplasia by methyl
methanesulphonate and ethyl methanesulphonate
R.J. Tudor, N.J. Severs* & R.M. Hicks
School ofPathology, The Middlesex Hospital Medical School, London WIP 7LD.
Summary The early and late morphological changes induced in rat bladder urothelium by intravesicular
administration of the alkylating agents methyl methanesulphonate (MMS) and ethyl methanesulphonate
(EMS) are described. In the short-term, both compounds produced dose-related toxic damage followed by a
regenerative hyperplasia of the urothelium. At any given dose-level, the effects of MMS were more severe
than those of EMS. Two years after administration of multiple doses of 2.5mg MMS or 7.5mg EMS the
majority of animals had dose-related simple urothelial hyperplasias with occasional mild dysplasia. However,
in three MMS-treated animals the hyperplasias had progressed to well-differentiated transitional-cell
carcinomas. No bladder neoplasms were seen in EMS-treated animals. The urothelial response of the rat to
MMS and EMS is discussed with reference to the known chemical reactivity of these compounds. It is
concluded that EMS is a mitogen for the urothelium and that the few carcinomas which develop following
topical exposure of the bladder to MMS do not necessarily reflect any initiating potential in this compound.
Rather it is argued that the results are consistent with MMS acting as a promoter in cells which have either
been previously initiated or which carry a latent oncogene.
Previous experiments in this laboratory established
that the alkylating agent N-methyl-N-nitrosourea
(MNU) is both a powerful hyperplastic agent and a
bladder carcinogen when administered by
intravesicular instillation (Hicks and Wakefield,
1972). This finding has provided a useful model
system in which the mechanisms of carcinogenesis
and the effects of modulators can be explored
(Hicks, 1980; Hicks et al.,1975, 1978; Severs et al.,
1982). Intravesicular instillation of two other
alkylating agents, viz. methyl methanesulphonate
(MMS) and ethyl methanesulphonate (EMS) in the
short-term produced toxic damage followed by
urothelial hyperplasia (Wakefield & Hicks, 1974).
Both EMS and MMS have been reported to
induce neoplasia in mice and rats following s.c. or
i.p. injection (data reviewed in IARC, 1974). In
rats, the lowest doses reported to produce tumours
following a single intraperitoneal injection were
100mgkg-1 EMS and 72mgkg- 1 MMS. EMS
produced mainly lung and kidney tumours whereas
MMS produced local tumours and tumours of the
nervous system. Oral administration of MMS to
mice for life was reported to increase the incidence
of lung tumours and lymphomas. Although there
was no indication that EMS and MMS were
carcinogenic for the urinary bladder, the fact that
in our previous work they were found to elicit
urothelial hyperplasia warrants further
investigation. The present study was therefore
undertaken to determine the short-term dose-
response of the rat bladder to single doses of EMS
and MMS, and to assess whether single or multiple
doses of these agents have any carcinogenic
potential for the urothelium in long-term trials.
Materials and methods
Chemicals
Methyl methanesulphonate (MMS) was obtained
from Cambrian Chemicals Ltd., Croydon, Surrey
and ethyl methanesulphonate (EMS) from Sigma
London Chemical Company Ltd., Poole, Dorset.
Both chemicals were used as supplied.
Animals and diet
Specific-pathogen-free female Wistar rats, free from
the bladder parasite, Trichosomoides crassicauda,
were supplied by A. Tuck and Son Ltd.
(Battlesbridge, Essex). They were caged in groups
of 6 in rooms kept at 19-220C with a relative
humidity of 50-60% and were maintained on
Dixon's standard pelleted 41B diet and tap water
ad libitum. The animals were 6-8 weeks old at the
beginning of treatment and weighed 135-175g.
They were observed daily for signs of ill health;
those that became ill and whose condition did not
improve were killed and subjected to post-mortem
examination.
Intravesicular administration ofagents
Fresh solutions of MMS and EMS were prepared
in Mcllvaine's citric acid/phosphate buffer (pH7.0)
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prior to each dosing session. Catheters were made
from 4cm lengths of Portex tubing (pplO, Portex
Ltd., Hythe, Kent) and sterilized in 70% ethanol.
Rats were anaesthetized by i.p. veterinary nemnbutal
(May and Baker Ltd., Dagenham, Essex), and a
catheter inserted via the urethra into the bladder of
each animal. To minimise any alteration in the
concentration of MMS or EMS by dilution with
urine in the bladder, micturition was induced by
gentle pressure to the lower abdomen.
The MMS and EMS solutions were instilled in a
volume of 0.15cm3 using a graduated syringe with
a 30G needle, which fitted into the end of the
catheter. After dosing, the catheter was gently
withdrawn from each bladder, and the animals
returned to cages where they were kept warm
during the recovery period.
Experimental design
Three experiments were carried out to investigate
the short-term effects of MMS and EMS on the
urothelium. In the first, rats each received a single
intravesical dose of 15mg (100mgkg-1) of EMS
and were killed at intervals of 2h, 4h, 1 day, 4
days and 7 days after treatment. In the second
experiment, single doses of 3.6mg (20mgkg-1) and
8.75 (50mgkg-1) of each compound were given
and the rats killed at 1 and 7 days post-dosing.
Single doses of 2.4mg (15mgkg-1) MMS and
6.2mg (35mgkg-1) EMS were used in the third
experiment and the animals killed at 1 and 7 days.
These experiments enabled a dose of each
compound to be selected which elicited a similar
biological effect, namely a moderate hyperplasia
with minimal toxic damage, for use in the long-
term trial. On the basis of the findings (see Results
section) a dose of 2.5mg was selected for MMS,
and 7.5mg for EMS.
For the long-term study, rats were randomly
distributed into 9 groups (A to I). Animals in
group A were not treated and were maintained as
the control group. Rats in groups B-E received one
to four doses of 2.5mg MMS, and those in groups
F-I received one to four doses of 7.5mg EMS. (See
Table I for details.) The multiple doses were
administered at intervals of 2 weeks.
Post-mortem procedures and tissue preparation
Animals that died during the study were autopsied,
unless this was precluded by ad-ianced autolysis or
cannibalism. Those found in extremis or surviving
to 2 years after the initial dose were killed by
cervical dislocation and their bladders exposed
through an abdominal incision. The urethra was
clamped and the bladder gently inflated by injection
of 0.5 cm3 of 10% phosphate-buffered formalin
(pH 7.4) into the lumen with a fine needle
introduced through the dome. Its serosal surface
was bathed with the same fixative and after 4
minutes fixation in situ the bladder was dissected
free.
After removal, the bladder was cut longitudinally
into two halves and examined under a dissecting
microscope for gross lesions (e.g. thickened areas,
tumours and calculi). In bladders of normal
macroscopic appearance, one half was further fixed
in 10% formalin prior to processing and embedding
in paraffin wax. Sections of 4gm were cut and
stained with haematoxylin and eosin. The other
half was cut into 1 mm3 blocks and post-fixed in
cold 0.1 M cacodylate-buffered 1% osmium
tetroxide. After dehydration at room temperature in
graded concentrations of alcohols, the tissue was
embedded in Spurr resin. Semi-thin (1 pm) sections
were cut and stained with toluidine blue for high
resolution light microscopy. At least three blocks
from each bladder were examined by this method
to complement the results obtained by conventional
histology.
In tumour-bearing bladders, areas of each
tumour and of the bladder wall were prepared for
both wax and resin embedding. Bladders from
animals that were found dead were processed for
wax-embedding only.
Results
Classification ofurothelial lesions
The typical appearance of normal urothelium
from an untreated control animal is shown in
Figure la. For assessment of both short-term and
long-term effects of MMS and EMS, urothelial
hyperplasia was defined as urothelium more than 3
cell layers thick. Simple hyperplasias were further
sub-divided into mild, moderate and marked
categories. Mild hyperplasia was defined as areas
4-6 cell layers thick (Figure lb), moderate
hyperplasia as areas 7-10 cells thick (Figure lc) and
marked hyperplasia as areas > 10 cell layers thick
(Figure Id). It was also noted whether the lesions
were focal or diffuse in nature, the lesions being
regarded as diffuse only when >20% of the
epithelium was hyperplastic. Nodular and papillary
hyperplasias were recorded as a separate category.
For each bladder, the grade of lesion recorded was
the most severe observed.
The diagnostic criteria for dysplasia, carcinoma
in situ, and invasive carcinomas are those currently
used in this laboratory and have been published
(Hicks et al., 1982).
Short-term effects ofMMS and EMS
Some degree of toxic damage including urothelialMMS AND EMS-INDUCED UROTHELIAL HYPERPLASIA 291
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Figure 1 Classification of urothelial hyperplasias, (a) normal bladder showing 3 cell thick urothelium; (b)
mild hyperplasia; (c) moderate hyperplasia; (d) marked hyperplasia. Toluidine blue-stained semi-thin sections.
(a) & (b), x 590; (c) & (d), x 230.
changes, necrosis, inflammation and oedema,
followed by a regenerative hyperplasia of the
urothelium was evident at all dose levels of MMS
and EMS. At any given dose level, the effects of
MMS were more severe than those of EMS. The
toxicity was dose-related and with higher doses the
resulting hyperplasias although delayed, were more
marked. There was some variation in the toxic
response, both within individual bladders and
between individual animals.
In the first short-term experiment, in which
MMS and EMS were administered at doses of
100mgkg-' (17.5mg per animal), toxic damage to
the urothelium was visible 2h after dosing. The
intercellular spaces were dilated, some cells were
vacuolated and there was focal desquamation of
many superficial cells. These effects were more
conspicuous at 4h and by 1 day much of the
urothelium had been stripped and some necrosis of
the underlying tissues was seen. There was
pronounced oedema and inflammation of the sub-
mucosa; the blood vessels, initially congested with
erythrocytes, subsequently ruptured causing
extensive haemorrhage. By 4 days, early focal
hyperplasia of the urothelium had developed
between remaining necrotic areas. Where
haemorrhage had occurred into overlying urothelial
tissue, erythrophagocytosis was observed as
previously reported (Wakefield & Hicks, 1974). At
7 days, some areas of the bladder were still necrotic
and, although the supporting stroma had been
partially restored by fibrosis, they were not yet re-
epithelialised. In adjacent areas, the regenerative
hyperplasia of the urothelium was moderate-to-
marked in nature.
In the second short-term experiment, in which
the effects of lower doses of MMS and EMS were
investigated, the condition of the bladder was
examined at 1 and 7 days after treatment. After
50mgkg-1 MMS, the toxic damage and resultant
a
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urothelial hyperplasia were similar to that observed
after a dose of 100mgkg-1. However, at lower
doses the severity both of the damage and of the
subsequent regenerative hyperplasia was reduced.
One day after 20mgkg-' MMS and 50mgkg-1
EMS, there was a loss of superficial and
intermediate cells leaving predominantly 1 cell thick
urothelium. In small focal areas, there was
complete stripping of the urothelium with necrosis
of the underlying stroma, but by 7 days, the
urothelium was hyperplastic to a moderate or
marked degree.
After 15mgkg-1 MMS, and 20 or 35mgkg-1
EMS, urothelial damage at 1 day was limited to
loss of the superficial and some intermediate cells.
Complete stripping was rare and if present was
confined to small localised areas. At 7 days, the
urothelial hyperplasia varied in severity from mild
and diffuse after the EMS (Figure 2a), to more
moderate and diffuse after the MMS (Figure 2b).
a
b
Figure 2 Typical appearance of the urothelium 7 days
after a single dose of 20mgkg-1 EMS (a) and
15mgkg- I MMS (b). Toluidine blue-stained semi-thin
sections. (a) x 190; (b) x 210.
In the short-term studies, gross haematuria was
observed 1 day after treatment with doses of
50mgkg-1 or more MMS, and with 100mgkg-1
EMS, but did not occur in animals receiving lower
doses of these compounds.
From these 3 short-term trials, it was established
that 15mgkg-' MMS (2.5mg per animal) and
between 35 and 50mgkg-1 EMS (6.2-8.75mg per
animal) were the lowest doses that would reliably
elicit moderate hyperplasia without haematuria and
extensive or persistent toxic damage. Therefore, for
the long-term trial in which multiple doses were to
be used, fraction sizes of 2.5mg MMS and 7.5mg
EMS were selected to give a comparable, relatively
uniform hyperplastic response.
Long-term trial
Most hyperplasias observed consisted simply of
thickened urothelium in which an orderly
differentiation from basal to superficial cell layers
was retained. Superficial cells were usually
flattened, although not necessarily differentiated,
but in more severe lesions the superficial cells often
appeared undifferentiated. Blood vessels were often
conspicuous at the base of the urothelium,
occasionally infiltrating into it, particularly in the
more severe hyperplasias (see Figure 4). With one
exception, nodular and papillary urothelial
hyperplasias were only observed in bladders where
carcinoma was also detected.
The total incidence of urothelial hyperplasia in
animals killed at 2 years was dose-related, both for
MMS and EMS (Figure 3 and Table I). The
fraction sizes selected, namely 2.5mg MMS and
7.5mg EMS, produced a remarkably comparable
response in the urothelium, as predicted from the
lOrO
F-_ : 80
.2
s 60
0
M
n 40
0
0)
CL
a)
*- 20 0
C
0L
0 *
A
L
0 1 2 3 4
Number of doses of agents
Figure 3 Incidence of urothelial hyperplasia in
response to single and multiple doses of 2.5mg MMS
(A) and 7.5mg EMS (0). Untreated control group
(OI) is shown for the zero dose.
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Table I Terminal pathology of the urothelium
State ofurothelium
% incidence (absolute number shown in parentheses)
Normal
Group Treatment
No. ofbladders
examined*
Hyperplastic
Mild Moderate PINA Total
None
1 x 2.5 mg MMS
2x2.5mg MMS
3 x 2.5 mg MMS
4x2.5mg MMS
1 x 7.5 mg EMS
2x7.5mg EMS
3x7.5mg EMS
4x7.5mg EMS
80
41
23
21
16
36
23
14
15
83.5(66)
51 (21)
35 (8)
14 (3)
19 (3)
56
30
29
20
(20)
(7)
(4)
(3)
14(11)
39(13)
35 (6)
57(11)
56 (8)
36(12)
48 (9)
71 (8)
80(10)
3.5(3)
7 (3)
26 (6)
19 (4)
25 (4)
5(1)
8 (3)
22 (5)
17.5 (14)
46 (19) 3(1)t
61 (14) 4(1)1
81 (17) 5(1)t
81 (13)
44
70
71
80
(16)
(16)
(10)
(12)
*Bladders were from rats surviving to 2 years after the initial dose plus those killed in extremis or found dead on
trial
AP/N refers to urothelial hyperplasias with a papillary/nodular growth pattern
tPapillary transitional cell carcinoma
$Papillary carcinoma in situ
short-term trials. However, the dose-related
response to EMS and MMS was less evident if the
hyperplasias were sub-divided into mild and
moderate. Thus, moderate hyperplasia was seen in
some animals after low but not after high doses of
EMS. Similarly, there was no clear dose-related
response in the incidence of each category of
hyperplasia after MMS; overall the lesions observed
were more severe than those seen after EMS
treatment. The majority of untreated control
bladders had normal urothelial differentiation,
although 11 animals had mild and 3 had moderate
focal hyperplasia (Table I). Mild dysplasias were
occasionally seen in urothelia from the control
group, but these were generally associated with
concomitant hyperplasia. In animals treated with
MMS and EMS, dysplasias were notably more
frequent and more severe both in urothelium of
normal thickness and in hyperplastic tissue. The
dysplasias were characterised by large indented
nuclei in the basal and intermediate layers, loss of
normal nuclear orientation and occasional large
multinucleate intermediate and binucleate basal
cells (Figures 5-7).
In one MMS-treated animal, the bladder was
lined by a grossly hyperplastic urothelium with a
papillary/nodular (P/N) growth pattern. (Figure 8).
The urothelium was well differentiated with
relatively few areas of dysplasia (Figure 9), and
although this was a borderline case, we classified it
as a hyperplastic, rather than a neoplastic lesion.
This bladder also contained a small free-lying
calculus.
Three urothelial carcinomas developed in MMS-
treated animals, but none in animals treated with
EMS. Two were isolated, large exophytic, well-
differentiated transitional-cell carcinomas of the
bladder with invasion of the papillary stalk (Pla)
(Figure 10). In one of these tumour-bearing
bladders there was a small area of squamous
metaplasia at some distance from the tumour
(Figure 11) and also a small free-lying calculus. The
third neoplasm was a carcinoma in situ in a ureter
proximal to the uretero-vesical junction. In this
lesion, the urothelium showed papillary hyperplasia
with focal areas of obvious nuclear pleomorphism
and disturbance of cellular polarity (Figure 12);
mitotic figures were prominent (Figure 13). There
was diffuse papillary hyperplasia of the bladder
urothelium in the same animal, but no sign of
urolithiasis.
Discussion
The short-term effects described here of instilling
either MMS or EMS into the bladder, confirm and
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Figures 4-7 Hyperplastic urothelium with blood vessel infiltration from a rat killed 2 years after a single
dose of 7.5mg EMS. (Figure 4). Features of mild urothelial dysplasia; irregular nuclear profiles (arrows,
Figure 5), multinucleate cells (arrows, Figure 6) and disorientated nuclei of variable size (arrows, Figure 7).
Toluidine blue-stained semi-thin sections. x 580.
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Figure 8 Survey view of a diffuse papillary/nodular hyperplasia from an animal given 3 instillations of
2.5mg MMS H & E-stained wax section. x40.MMS AND EMS-INDUCED UROTHELIAL HYPERPLASIA 295
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Figure 9 Semi-thin section showing fine detail of the
Figure 8. Toluidine blue-stained. x 180.
extend the preliminary observations of toxic
damage followed by urothelial hyperplasia reported
previously (Wakefield & Hicks, 1974). The present
study shows the severity and time-course of the
response to both agents to be dose related. The
effects of MMS were consistently more severe than
those of EMS, and in order to elicit the same
degree of moderate hyperplasia with minimal toxic
damage, a three-fold dose of EMS was required by
comparison with MMS (i.e. 7.5mg and 2.5mg
respectively). These findings are in accord with the
toxic effects produced by systemic administration of
EMS and MMS (LDSO values of 434mgkg-1 and
180 mgkg'- respectively (Frei, 1971) (see footnote a).
In mutagenicity tests also, alkylating agents
which react chemically via an SN2 mechanism are
more cytotoxic than those reacting via an SN1
hyperplastic urothelium from the same bladder as in
mechanism (see footnote b) (Pegg, 1977). MMS is a
typical SN2 type agent, whereas EMS shows both
SNI and SN2 characteristics (Lawley, 1976). The
cytotoxic and hyperplastic effects of these
compounds instilled directly into the bladder thus
reflect their direct chemical reactivity.
For the long-term experiments, doses of MMS
and EMS were selected which gave a virtually
identical dose-response pattern in terms of the total
numbers of proliferative lesions produced. In
addition to its strong hyperplastic activity MMS,
but not EMS, was weakly carcinogenic for the
urothelium. Topical exposure of the bladder to
bFor SNI reagents the rate-limiting step is ionisation to a
carbonium ion which, being extremely electrophilic, can
bind with all nucleophilic centres in the DNA. SN2
reagents do not form an intermediate carbonium ion and
the transition complex formed has a relatively low
electrophilic reactivity. They therefore tend to react more
exclusively at the major nucleophilic centre in DNA, i.e.
N7 of guanine.
aThe LD50 value of 880mgkg-1 for EMS given in Frei,
1971, was a printer's error. (Personal communication from
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Figure 10 One of two large exophytic transitional cell carcinomas observed after MMS treatment
(1 x 2.5mg). H & E-stained wax section. x 16.
MNU leads to formation of both 7-methylguanine
and 06-methylguanine in urothelial DNA, but since
the enzymatic excision of 06-methylguanine takes
place at a slower rate than does the repair of other
DNA adducts (Cox & Irving, 1977), it is this
particular adduct which persists. There is now
considerable evidence to support the hypothesis of
Loveless (1969) that 06-alkylation of guanine is an
important cause of miscoding in DNA and hence of
mutation and tumour induction (reviewed by
Lawley, 1976). In experiments where the alkylating
agents were administered systemically and a range
of organs were examined (e.g. brain, liver and
thymus), MMS and EMS by comparison with
MNU produced little alkylation at the 06 position
of guanine and their major alkylation products
were 7-methylguanine and 7-ethylguanine
respectively (Frei & Lawley, 1976; Frei et al., 1978).
Nevertheless, both MMS and EMS are carcinogenic
in a variety of organ systems, although they are far
less potent than MNU (IARC, 1974). Working on
the assumption that differences in carcinogenic
activity may be related to the ability of the agent to
alkylate the 06 position of the guanine residue in
DNA, Frei et al. (1978), using a thymic lymphoma
model, calculated that the ratio of equipotent doses
pp,MMS AND EMS-INDUCED UROTHELIAL HYPERPLASIA
Figure 11 An area of squamous metaplasia with keratinization from the same bladder as that bearing the
tumour illustrated in Figure 10. H & E-stained wax section. x 170.
iT._ 41
Figure 12 Low power view of the ureter in which carcinoma in situ was detected. Gross papillary hyperplasia
is evident with dysplastic areas. From an animal treated with 2 x 2.5mg MMS. H & E-stained wax section.
x 160.
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Figure 13 High power view of an area from the ureter featured in Figure 12. The urothelium shows
increased cellularity with disorientated pleomorphic cells and the presence of abnormal mitoses (arrows). The
lesion was classified as carcinoma in situ. H & E-stained wax section. x 480.
of EMS and MMS by comparison with MNU
would be 21 and 144 respectively. If the induction
of bladder cancer by these alkylating agents
depends solely on the formation of 06_
methylguanine in urothelial DNA, then the data of
Frei et al. (1978) predict that, as we confirmed, of
the three MNU should be the most powerful
carcinogen for the urothelium. However, they also
predict that EMS should be considerably more
carcinogenic than MMS, which is the reverse of
what we found. Considered together, these
observations indicate that after topical application
of these alkylating agents to the urothelium, the
carcinogenic response may not depend solely on
their ability to alkylate DNA, but may reflect other
biological phenomena.
Analysis of the proliferative response of the
urothelium reveals some interesting differences in
the effect of EMS and MMS on this tissue. With
both compounds, the total number of proliferative
lesions produced gave excellent dose-related
measure of exposure (Figure 4). With EMS,
however, none of the hyperplasias showed
abnormal growth patterns or gross dysplasia and
the more severe lesions were found after the lower
rather than after the higher dose levels. These
expanded populations of normal urothelial cells
represent the response of the urothelium to the
cytotoxic damage caused by EMS and the absolute
thickness of the urothelium will depend on the
balance between the rates of cell death and of cell
regeneration. The absence of marked dysplasia,
abnormal growth patterns or any other signs of
possible neoplastic conversion, implies that
whatever the reaction may be between topically-
applied EMS and the urothelial target cell DNA, it
is not a mutagenic event.
MMS, on the other hand, as well as inducing flat
proliferative response also produced four lesions
with abnormal growth patterns, either P/N
hyperplasia or papillary carcinoma. Admittedly, all
were well differentiated and not aggressively
invasive, i.e. they were comparable to the relatively
benign papillomas produced by promoters acting
on skin previously initiated by exposure to a
carcinogen. This raises the possibility that MMS,
unlike EMS which acts as a mitogen, may have
some other specific effect on the urothelial cells.
The lack of a clear-cut dose-related carcinogenic
response of the urothelium to MMS does not
support the theory that MMS is acting as an
initiating carcinogen like MNU. It is also consistent
with the fact that MMS is the least effective of the
three alkylating agents at inducing point mutationsMMS AND EMS-INDUCED UROTHELIAL HYPERPLASIA 299
in bacteria (Loveless, 1969). Rather, the results
support the hypothesis that MMS may act as a
promoter and in some way permit expression of
damage produced by exposure to low doses of
unidentified "environmental" carcinogens or of a
latent cancer gene in one or more cells in the
hyperplastic urothelium. It is noteworthy that
MMS is considerably more powerful than EMS in
inducing sister chromatid exchange and
chromosomal aberrations when tested in a Chinese
hamster fibroblast model system (Perry and Evans,
1975), and that increased sister chromatid and
homologous chromosome exchange has been
implicated in tumour promotion (Kinsella and
Radman, 1978). Furthermore, saccharin, an
effective promoter of carcinogenesis in the initiated
rat bladder, also causes the development of a few
urothelial tumours in otherwise normal bladders
when given on its own (Hicks et al, 1978).
Saccharin is not mutagenic but, like MMS, does
cause sister chromatid exchange (Albe and Sakaki,
1977; Wolff and Rodin, 1978). If a genetic event of
this sort which is not a new mutation can result in
tumour formation, this is evidence per se either that
the rat urothelium carries a latent oncogene, or as
we have suggested elsewhere (Chowaniec and
Hicks, 1979), that most animal populations are
exposed to low levels of undetected environmental
initiating carcinogens.
This study of topically-applied EMS and MMS
in the urinary bladder indicates that EMS is
primarily a mitogen for the urothelium. By analogy
with the mouse skin model (Boutwell et al., 1982)
the effect of EMS on the bladder may be
comparable to that of hyperplastic agents on the
skin. In that system, it was demonstrated that
hyperplastic agents (e.g. turpentine,
ethylphenylpropiolate, etc.) are unable to cause
tumour growth from initiated cells unless in
addition the tissue has been "promoted". Following
initiation plus promotion such agents will, however,
accelerate tumour development. By contrast with
EMS, in the bladder MMS besides being a mitogen
also permits the development of a few tumours.
The absence of a dose-related carcinogenic response
to MMS is indicative that MMS is not an initiating
carcinogen in this tissue and we therefore suggest
that these observations more probably reflect a
promoting effect of MMS on a latent oncogene or
previously initiated cell.
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